Point of Care Diagnostics Industry - Regional Synopsis
North America Market Analysis
North America is predicted to capture the largest share of 38.3% in the point of care diagnostics market over the discussed timeframe. The region's leadership is primarily attributable to the presence of a robust medical infrastructure and a supportive Federal government. The efforts from dedicated authorities to improve public access to early detection, treatment, and prevention, to combat the continuously emphasizing patient pool, is securing a reliable cash inflow in this sector. For instance, in 2024, the governing body of Ontario allocated USD 220.3 million in funds to expand the accessibility of POC devices among 300,010 residents from rural areas. Similarly, governments in clinically developed countries, such as the U.S. and Canada, are reforming the policy structure for reimbursements and subsidies to serve the same purpose.
The U.S. complements the regional expansion in the market through continuous expansion in Medicare & Medicaid coverage and acceptance of advanced POC technologies. For instance, in 2024, the U.S. Medicare spending on these tests reached up to USD 2.0 billion, where more than 11 new assay types were covered. On the other hand, in 2024, the accelerated FDA clearances for AI-integrated POC devices boosted their adoption across the nationwide network of clinics by 45.3%. Additionally, with robust financial support from both consumers and the Federal government, the country is maintaining its overwhelming leadership in North America.
APAC Market Statistics
The Asia Pacific point of care diagnostics market is poised to exhibit the highest CAGR by the end of 2037. Its pace of emergence is highly stimulated by escalating public health investments, infrastructural development, and digital healthcare transformation in developing countries, such as China and India. For instance, in 2024, India portrayed its potential as a large consumer base in this sector by commencing the National Health Mission, delivering over 5.1 million annual TB and HIV POC tests. Similarly, in 2025, the National Medical Products Administration (NMPA) in China drafted and released the Healthy China 2030 program. Its roadmap has a USD 12.4 billion outlay, intending to support rural POC initiatives across the country. In addition, AI-based innovations are the region's strong propagation in this field.
Japan is becoming the hub of technological discoveries in the market, driven by the vast AI adaptation in healthcare. Considering the clinical benefits of incorporating automation in the process of analyzing, detecting, and evaluating patient data, the root cause of the ailment, and treatment prognosis, the government is allocating significant capital in this sector. For instance, in 2024, over 12.4% of its healthcare budget (up to USD 4.0 billion) was dedicated to advances in POC technologies, as per the Ministry of Health, Labour and Welfare. Besides, the regulatory support is also accountable to the nation's progressive business environment. For instance, in 2024, the fast-track approval from the PDMA minimized molecular POC test-related delays by 6 months.
